SideROS
SideROS is an early-stage, privately held French biotechnology company founded in 2019 in Paris, operating with a 1–10 person team led by founder Raphaël Rodriguez and COO Lucie Mondoulet, and funded to date primarily by 2020 non-dilutive grants from Bpifrance and Région Ile-de-France alongside a small seed round.
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
SideROS firmographics
Firmographics- Name
- SideROS
- Website
- https://sideros.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SideROS is an early-stage, privately held French biotechnology company founded in 2019 in Paris, operating with a 1–10 person team led by founder Raphaël Rodriguez and COO Lucie Mondoulet, and funded to date primarily by 2020 non-dilutive grants from Bpifrance and Région Ile-de-France alongside a small seed round.
- Ownership category
- akta.pro rank
SideROS industry classification
Industry- Product category
- Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where SideROS is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
SideROS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
SideROS product offering
Product offeringCore offering
SideROS is a privately held biotechnology company based in Paris, France, founded in 2019. The company operates in the life sciences sector with a workforce of 1-10 employees. Specific product, pipeline, and scientific focus details are not publicly disclosed in available source material.
Differentiator
Problem solved
Functional benefit
Companies that use SideROS
Customer profileIdeal customer profiles1 record
SideROS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SideROS competitors and assessment
Company assessmentDirect peers
- DBV Technologies: French-listed biotech developing immunology/epicutaneous-delivery products out of academic science. Comparable French biotech peer with similar founder-from-academia origin and Bpifrance-style public funding in its history.
- Disc Medicine: US-based clinical-stage biotech focused on hematologic diseases driven by iron metabolism. Most comparable to SideROS given the shared focus on iron-biology mechanisms and translational drug development on the same biological axis the founder's lab works on.
- Transgene: French clinical-stage biotech developing immunotherapies (oncolytic viruses, TCR therapies) for cancer. A direct oncology-focused French biotech peer with overlapping institutional investors and licensing/exit optionality into major EU pharma.
- Cellectis: Paris-based clinical-stage gene-editing and cell-therapy biotech. Relevant French peer with shared academic-founder dynamics, Paris HQ, and Bpifrance/public-funder backing, providing a comparable development and capital-structure reference point.
- Innate Pharma: Marseille-based publicly listed French biotech developing immuno-oncology therapeutics. Comparable as a French oncology-biotech peer at similar development stages and ecosystem (public French biotech funding, academic founders, French VC backing).
- Genfit: French publicly-listed biotech with metabolic-disease pipeline. Comparable as a French for-profit biotech that leverages academic science and public French funding ecosystems, providing a regional governance and funding benchmark.
Emerging players
- Abionyx Pharma: Toulouse-based publicly-listed French biotech developing bio-HDL-based therapeutics, with a focus on metabolic and ophthalmology indications. A regional French peer of similar small-cap size operating in translational biotech, useful as a comparable for early-stage French biotech public/private dynamics.
Broad incumbents
- Sanofi: Paris-headquartered global pharma with deep oncology, immunology, and rare-disease R&D. Relevant incumbent comparator for talent, partnership, and M&A pathways for Paris-based biotechs in oncology, including potential future collaboration with SideROS.
- Ipsen: Paris-headquartered global specialty pharma with significant oncology and rare-disease franchises. Acts as a potential acquirer / licensing partner for French oncology biotechs like SideROS, and is the relevant incumbent comparator for any partnership or exit path.
- Servier: French privately-held global pharma with oncology as a core franchise. Comparable incumbent for partnership/licensing dynamics for French oncology biotechs, and a logical partner/counterparty for any platform originating from Institut Curie science.
Market position
Customer concentration
SideROS social profiles
Digital presenceSideROS financial estimates
Financial estimateRevenue estimate
Valuation estimate
SideROS leadership team
Management profileNumber of profiles
Profiles2 records
SideROS funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SideROS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SideROS
What does SideROS do?
SideROS is a privately held biotechnology company based in Paris, France, founded in 2019. The company operates in the life sciences sector with a workforce of 1-10 employees. Specific product, pipeline, and scientific focus details are not publicly disclosed in available source material.
Is SideROS a public or private company?
SideROS is a private company. It is classified as venture growth investor backed and is currently operating.
When was SideROS founded?
SideROS was founded in 2019. It employs 1 to 10 people.
Where is SideROS based?
SideROS is headquartered in Paris, France, in the Europe region.
Who are SideROS's main competitors?
Direct peers on record are DBV Technologies, Disc Medicine, Transgene, Cellectis, Innate Pharma and Genfit. Abionyx Pharma is listed as an emerging player. Broad incumbents are Sanofi, Ipsen and Servier.
Does SideROS have an API?
No public API is recorded for SideROS.
What industry is SideROS in?
SideROS's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.